Flex Pharma Inc. (FLKS) and Clovis Oncology Inc. (NASDAQ:CLVS) Comparison side by side

Flex Pharma Inc. (NASDAQ:FLKS) and Clovis Oncology Inc. (NASDAQ:CLVS), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Flex Pharma Inc. N/A 15.14 15.93M -1.22 0.00
Clovis Oncology Inc. 109.98M 6.24 376.74M -7.16 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Flex Pharma Inc. and Clovis Oncology Inc.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Flex Pharma Inc. 0.00% -155.3% -128.1%
Clovis Oncology Inc. -342.55% -196.4% -43%

Risk & Volatility

Flex Pharma Inc. is 77.00% more volatile than S&P 500 due to its 1.77 beta. Competitively, Clovis Oncology Inc. is 85.00% more volatile than S&P 500, because of the 1.85 beta.

Liquidity

The current Quick Ratio of Flex Pharma Inc. is 8.8 while its Current Ratio is 8.9. Meanwhile, Clovis Oncology Inc. has a Current Ratio of 4.4 while its Quick Ratio is 4.2. Flex Pharma Inc. is better positioned to pay off its short-term and long-term debts than Clovis Oncology Inc.

Analyst Ratings

The Ratings and Recommendations for Flex Pharma Inc. and Clovis Oncology Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Flex Pharma Inc. 0 0 0 0.00
Clovis Oncology Inc. 0 2 3 2.60

On the other hand, Clovis Oncology Inc.’s potential upside is 123.94% and its consensus price target is $29.

Institutional & Insider Ownership

The shares of both Flex Pharma Inc. and Clovis Oncology Inc. are owned by institutional investors at 13.7% and 0% respectively. Insiders held 16.9% of Flex Pharma Inc. shares. Insiders Competitively, held 0.5% of Clovis Oncology Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Flex Pharma Inc. -0.96% -35.72% 25.3% -22.03% -89.28% 21.58%
Clovis Oncology Inc. -6.06% -8.66% -25.22% 19.94% -62.48% 4.51%

For the past year Flex Pharma Inc.’s stock price has bigger growth than Clovis Oncology Inc.

Summary

Flex Pharma Inc. beats Clovis Oncology Inc. on 7 of the 10 factors.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier; and a clinical collaboration with Bristol-Myers Squibb Company to evaluate combination of Opdivo (Nivolumab) and Rubraca (rucaparib) in Phase 2 and pivotal Phase 3 clinical trials in multiple tumor types. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.